L'intérêt à découvert pour Teleflex donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Teleflex. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Teleflex (NYSE:TFX) Stock, Rapport sur les intérêts à découvert

Teleflex

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.

Teleflex Inc

On Thursday, Teleflex Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) will pursue a plan to separate into two new, independent, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44001713/teleflex-announces-intent-to-separate-into-two-publicly-traded-companies" rel="noreferrer noopener">publicly traded companies</a>:
<ul>
<li>New, independent, publicly traded company (NewCo) consisting of Teleflex&#8217;s Urology, Acute Care, and OEM businesses.</li>
<li>RemainCo will consist of Teleflex&#8217;s Vascular Access, Interventional, and Surgical businesses, focusing on high-growth, high-acuity, primarily hospital-focused emergent end markets.</li>
</ul>
The separation is expected to be completed by mid-2026.
&#8220;Following the separation, RemainCo will be well-positioned to accelerate growth in attractive, primarily hospital-focused, emergent end markets, with a simplified operating model, streamlined manufacturing footprint, and increased management focus,&#8221; said Liam Kelly, Teleflex&#8217;s Chairman, President, and CEO.
RemainCo had approximately $2.1 billion in revenue in 2024.
Concurrently, Teleflex agreed to acquire the Vascular Intervention business of Biotronik SE &amp; Co. KG for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44001607/teleflex-to-acquire-biotroniks-vascular-intervention-business" rel="noreferrer noopener">approximately 760 million euros</a> ($791.6 million). The acquisition is expected to be completed by the end of the third quarter of 2025.
RemainCo is expected to generate constant currency revenue growth of over 6%. RemainCo will have a simplified and nimble operating model with a streamlined manufacturing footprint, transitioning from 19 manufacturing facilities anticipated at Teleflex as of year-end 2025 to 7 facilities at RemainCo post-separation, with the remaining 12 expected to transfer to NewCo.
The transaction is also expected to be accretive to EPS growth, with RemainCo anticipated to deliver double-digit EPS growth in the first full year following the separation.
NewCo, with approximately $1.4 billion in revenue in 2024, is also expected to benefit from a simplified operating model. NewCo is expected to generate low-single digit constant currency revenue growth with a mid-50% adjusted gross margin profile.
Teleflex will initiate an executive search for key management positions at NewCo shortly.
Teleflex also reported fourth-quarter sales of $795.4 million, up 2.8% year over year (+3.2% on constant currency), missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $813.23 million</a>. The medical devices company reported adjusted EPS of $3.89, beating the consensus of $3.86.
Guidance: Teleflex expects 2025 revenue growth of (0.4)% to 0.7%, with adjusted EPS of $13.95-$14.35 versus <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44001824/teleflex-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">consensus of $15.23</a>.
CFO transition: Teleflex announced that Thomas Powell, the company&#8217;s CFO, will retire, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44001775/teleflex-announces-planned-retirement-of-thomas-powell-as-chief-financial-officer" rel="noreferrer noopener">effective April 1</a>. John R. Deren, currently serving as Corporate Vice President and Chief Accounting Officer, will succeed Mr. Powell as Executive Vice President and Chief Financial Officer, effective April 2.
Price Action: TFX stock is down 21.6% at $139.35 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/44008563/donaldson-q2-earnings-miss-aftermarket-and-life-sciences-segments-shine-amid-q2-revenue-dip" target="_blank" rel="noreferrer noopener">Donaldson Q2 Earnings Miss: Aftermarket And Life Sciences Segments Shine Amid Revenue Dip</a></li>
</ul>

Earnings

Large Cap

News

Guidance

Health Care

Management

Movers

Trading Ideas

General

Teleflex Hits 52-Week Low On Plan To Split Into Two Companies, Reports Mixed Q4 Earnings

WIIM

Teleflex shares are trading lower after the company issued FY25 EPS guidance below estimates.

2025 guidance summary
<ul>
<li>GAAP revenue growth guidance range of (0.4)% to 0.7%</li>
<li>Adjusted constant currency revenue growth guidance range of 1.0% to 2.0%, which excludes the 2024 impact from increases in our reserves related to the Italian payback measure pertaining to prior years</li>
<li>GAAP EPS from continuing operations guidance range of $8.85 to $9.25.</li>
<li>Adjusted diluted EPS from continuing operations guidance range of $13.95 to $14.35</li>
</ul>
"In the fourth quarter, we delivered strong double-digit adjusted earnings per share growth" said Liam Kelly, Teleflex's Chairman, President and Chief Executive Officer. "The benefits of our diversified portfolio were evident as strong performances from Interventional and Surgical helped offset softness in Interventional Urology revenues. Palette Life Sciences revenues exceeded $75 million in 2025, which was above the $73-$75 million guidance. As announced in a separate press release today, we also took an important step forward in our durable growth strategy with the agreement to acquire substantially all of BIOTRONIK's Vascular Intervention business. This acquisition provides us with a diversified suite of products of coronary and peripheral interventions devices, which complements the Teleflex Interventional business. Also announced today in a separate press release is our intention to separate Teleflex into two publicly traded companies, RemainCo and NewCo. The separation is expected to simplify the operating model, streamline the manufacturing footprint, and increase management focus of each company."

Teleflex Expects 2025 Revenue Growth Of (0.4)% To 0.7%, With Adjusted EPS Of $13.95-$14.35 Versus Consensus Of $15.23

Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) reported quarterly earnings of $3.89 per share which beat the analyst consensus estimate of $3.86 by 0.78 percent. This is a 15.09 percent increase over earnings of $3.38 per share from the same period last year. The company reported quarterly sales of $795.41 million which missed the analyst consensus estimate of $813.23 million by 2.19 percent. This is a 2.78 percent increase over sales of $773.90 million the same period last year.

Teleflex Q4 2024 Adj EPS $3.89 Beats $3.86 Estimate, Sales $795.41M Miss $813.23M Estimate

&nbsp;Following his retirement, Mr. Powell will serve as a consultant to the company through March 31, 2026 to support continuity and a smooth transition.

Teleflex Announced That Thomas Powell Will Retire As EVP And CFO, Effective April 1. John Deren, Currently The Corporate Vice President And Chief Accounting Officer Of Teleflex, Will Become EVP And CFO, Effective April 2

Teleflex to create a new, independent publicly traded company ("NewCo") consisting of Teleflex's Urology, Acute Care, and OEM businesses.
Teleflex RemainCo ("RemainCo") will consist of Teleflex's Vascular Access, Interventional, and Surgical businesses – focusing on high-growth, high-acuity, primarily hospital-focused emergent end markets.

Teleflex Plans To Separate Into Two Publicly Traded Companies

The acquisition reflects Teleflex's commitment to investing in the estimated $10 billion interventional cardiology and peripheral vascular market served by the Company's portfolio post close.1,2 The acquired business will expand the Teleflex Interventional portfolio to include a broad suite of vascular intervention devices such as drug-coated balloons, drug-eluting stents, covered stents, balloon and self-expanding bare metal stents, and balloon catheters. In 2023, approximately 75% of the acquired revenues were generated by coronary interventions while the remaining approximately 25% were associated with peripheral interventional procedures.3

Teleflex Agrees To Acquire Vascular Intervention Business Of Biotronik For Approximately €760M; The Acquisition Is Expected To Be Completed By The End Of The Third Quarter Of 2025

AAON

ABCL

ACEL

ACHC

ACHR

ACIC

ACIW

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CDXS

CLCO

CLOV

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

CYTK

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

Teleflex's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) short percent of float has risen 31.52% since its last report. The company recently reported that it has 1.05 million shares sold short, which is 3.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Teleflex Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739288726_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teleflex has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Teleflex's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teleflex's peer group average for short interest as a percentage of float is 3.66%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Teleflex?

Contracts

Teleflex Has Been Awarded A Contract By Vizient Covering The Supply Of Teleflex's Central Venous Access Catheters And Arterial Catheters

Teleflex's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) short percent of float has risen 12.35% since its last report. The company recently reported that it has 554 thousand shares sold short, which is 1.91% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.34 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Teleflex Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736280024_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teleflex has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Teleflex's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teleflex's peer group average for short interest as a percentage of float is 3.94%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

In the current session, Teleflex Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) is trading at $180.00, after a 0.08% decrease. Over the past month, the stock decreased by 6.59%, and in the past year, by 28.07%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1735308911_0.png" alt="Past Year Chart" />

<h3>How Does Teleflex P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 67.67 in the Health Care Equipment &amp; Supplies industry, Teleflex Inc. has a lower P/E ratio of 35.74. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1735308911_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for Teleflex

Truist Securities analyst Richard Newitter maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold and lowers the price target from $227 to $200.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Teleflex, Lowers Price Target to $200

In the last three months, 5 analysts have published ratings on Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $250.4, a high estimate of $275.00, and a low estimate of $227.00. Experiencing a 4.57% decline, the current average is now lower than the previous average price target of $262.40. 
<img src="https://www.benzinga.com/files/images/story/2024/1734375625_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Teleflex's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$227.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$245.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$255.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$275.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Teleflex. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teleflex compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Teleflex's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Teleflex's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TFX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teleflex analyst ratings.</a>
<h2>Unveiling the Story Behind Teleflex</h2>
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
<h3>Teleflex: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Teleflex displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 2.41%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teleflex's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 14.52%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Teleflex's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.46%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Teleflex's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.49%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Teleflex's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.42.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Teleflex Stands With Analysts

Needham analyst Mike Matson reiterates Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Teleflexto Hold

Teleflex Is Said To Offer €500M To €1B For Biotronik Unit

Truist Securities analyst Richard Newitter reiterates Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold and lowers the price target from $255 to $227.

Truist Securities Reiterates Hold on Teleflex, Lowers Price Target to $227

Mizuho analyst Anthony Petrone maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Neutral and lowers the price target from $275 to $250.

Mizuho Maintains Neutral on Teleflex, Lowers Price Target to $250

RBC Capital analyst Shagun Singh maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Outperform and lowers the price target from $275 to $245.

RBC Capital Maintains Outperform on Teleflex, Lowers Price Target to $245

Needham analyst Mike Matson reiterates Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold.

Needham Reiterates Hold on Teleflex

Press Releases

Teleflex awarded Short Term Central Venous Catheters contract from Vizient

Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

Teleflex Announces Fourth Quarter 2024 Earnings Conference Call Information

Teleflex to Present at the Raymond James & Associates 46th Annual Institutional Investors Conference

Teleflex to Acquire BIOTRONIK's Vascular Intervention Business

Teleflex Announces Intent to Separate into Two Publicly Traded Companies

Teleflex Announces Planned Retirement of Thomas Powell As Chief Financial Officer

Teleflex Reports Fourth Quarter and Full Year 2024 Financial Results

Dividends

Teleflex Announces Quarterly Dividend

TFX BREAKING NEWS: Teleflex Incorporated 20% Stock Drop Triggers Securities Fraud Investigation; Investors are Urged to Contact BFA Law if they Suffered Losses

Comments

Teleflex

Intérêt court

Teleflex (NYSE:TFX) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL